Ftse Mib
35.090,23
-0,64%
DAX
20.214,79
-0,51%
S&P 500
5.827,04
-1,54%
NASDAQ
19.161,63
-1,63%
Bitcoin
94.299,68
-0,29%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ALX Oncology Holdings Inc (ALXO) ALX Oncology Holdings Inc (ALXO) Notizie

ALX Oncology Holdings Inc

ALXO
1,82
-0,03 (-1,62%)
11 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/1/202522:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/1/202514:00GLOBEALX Oncology to Present at the 43rd Annual J.P. Morgan..
02/1/202522:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202522:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/12/202422:12EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
18/12/202414:00GLOBEALX Oncology to Present Updated Results from Phase 2..
12/12/202414:00GLOBEALX Oncology to Host Virtual Company Event Highlighting New..
10/12/202415:00GLOBEALX Oncology Announces New Data Demonstrating Evorpacept in..
04/12/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/12/202422:06EDGAR2Form SC TO-I - Tender offer statement by Issuer
26/11/202414:00GLOBEALX Oncology to Participate in the Piper Sandler 36th Annual..
19/11/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202414:03EDGAR2Form 8-K - Current report
14/11/202414:00GLOBEALX Oncology Appoints Alan Sandler, M.D., as Chief Medical..
07/11/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202422:03EDGAR2Form 8-K - Current report
07/11/202422:00GLOBEALX Oncology Reports Third Quarter 2024 Financial Results..
04/11/202414:00GLOBEALX Oncology Announces November Investor Conference..
01/11/202422:30GLOBEALX Oncology Announces Results from Phase 1b/2 Trial of..
04/10/202415:00EDGAR2Form 8-K - Current report
09/9/202414:00GLOBEALX Oncology to Present at the 2024 Cantor Fitzgerald Global..
04/9/202414:00GLOBEALX Oncology Announces First Patients Dosed with Evorpacept..
16/8/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:08EDGAR2Form 8-K - Current report
08/8/202422:05GLOBEALX Oncology Reports Second Quarter 2024 Financial Results..
07/8/202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202423:22EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/8/202422:45EDGAR2Form 8-K - Current report
06/8/202422:01GLOBEALX Oncology Appoints Alan Sandler, M.D., to Board of..
31/7/202422:01GLOBEALX Oncology Reports Topline Data From ASPEN-06 Phase 2..
31/7/202411:30GLOBEALX Oncology to Host Investor Call and Webcast to Share..
15/7/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/7/202422:23EDGAR2Form 144 - Report of proposed sale of securities
09/7/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:21EDGAR2Form 8-K - Current report
06/6/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:14EDGAR2Form 144 - Report of proposed sale of securities
02/6/202416:00GLOBEALX Oncology Presents First Evorpacept Combination Data with..
29/5/202415:00GLOBEALX Oncology Announces Participation in the Jefferies Global..
15/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:06EDGAR2Form 144 - Report of proposed sale of securities
09/5/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:00GLOBEALX Oncology Reports First Quarter 2024 Financial Results..
08/5/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:00GLOBEALX Oncology Appoints Allison Dillon as Chief Business..
06/5/202422:02EDGAR2Form 144 - Report of proposed sale of securities
30/4/202415:00GLOBEALX Oncology Announces Initiation of Phase 2..
Apertura: 1,84 Min: 1,71 Max: 1,865
Chiusura: 1,85

La tua Cronologia

NASDAQ
ALXO
ALX Oncology
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network